Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Autoimmune cholangitis.

E J Heathcote1

  • 1Department of Medicine, University of Toronto, Toronto, Canada.

Clinics in Liver Disease
|November 25, 2004
PubMed
Summary
This summary is machine-generated.

Autoimmune cholangitis shares features with primary biliary cirrhosis (PBC) but lacks anti-mitochondrial antibodies (AMA). This condition, characterized by antinuclear antibodies, responds similarly to ursodeoxycholic acid treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pegylated interferon plus optimized weight-based ribavirin dosing negate the influence of weight and body mass index on early viral kinetics and sustained virological response in chronic hepatitis C.

Journal of viral hepatitis·2010
Same author

Prognosis of hepatitis C virus-infected Canadian post-transfusion compensation claimant cohort.

Journal of viral hepatitis·2009
Same author

Transient development of anti-mitochondrial antibodies accompanies autoimmune hepatitis-sclerosing cholangitis overlap.

Gut·2008
Same author

When to treat and the benefits of treating hepatitis C in patients with haemophilia.

Haemophilia : the official journal of the World Federation of Hemophilia·2008
Same author

The genetic study of primary biliary cirrhosis: great hope, some caution.

Current gastroenterology reports·2008
Same author

Primary Biliary Cirrhosis (PBC). Preface.

Clinics in liver disease·2008

Area of Science:

  • Hepatology
  • Immunology
  • Autoimmune Diseases

Background:

  • Primary biliary cirrhosis (PBC) is often associated with anti-mitochondrial antibodies (AMA).
  • Some patients present with PBC-like characteristics but are AMA-negative, instead testing positive for antinuclear antibodies (ANA).
  • These ANA-positive patients are sometimes referred to as having autoimmune cholangitis.

Purpose of the Study:

  • To evaluate the clinical characteristics, disease course, and treatment response of patients with autoimmune cholangitis (ANA-positive PBC).
  • To compare autoimmune cholangitis with AMA-positive PBC regarding associated autoimmune diseases and response to ursodeoxycholic acid.
  • To assess the utility of the term "autoimmune cholangitis" as a distinct or stratified classification within PBC.

Main Methods:

Related Experiment Videos

  • Review of clinical, biochemical, and histological data of patients with autoimmune cholangitis.
  • Serial testing for AMA in patients initially diagnosed with autoimmune cholangitis.
  • Comparison of disease progression and extrahepatic manifestations between AMA-positive and AMA-negative (autoimmune cholangitis) PBC cohorts.
  • Assessment of treatment response to ursodeoxycholic acid in both groups.

Main Results:

  • Patients with autoimmune cholangitis exhibit clinical, biochemical, and histological features similar to AMA-positive PBC.
  • Autoimmune cholangitis patients remain AMA-negative upon serial testing.
  • The spectrum of associated non-hepatic autoimmune diseases is comparable between AMA-positive and autoimmune cholangitis patients.
  • Ursodeoxycholic acid demonstrates comparable efficacy in both AMA-positive PBC and autoimmune cholangitis.

Conclusions:

  • Autoimmune cholangitis represents a distinct entity or a specific subtype of PBC characterized by ANA positivity and AMA negativity.
  • The disease course, associated conditions, and treatment response are similar to AMA-positive PBC.
  • The term "autoimmune cholangitis," potentially stratified by AMA status, may be a more accurate descriptor than "primary biliary cirrhosis" for these patients.